UY37160A - COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 - Google Patents

COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6

Info

Publication number
UY37160A
UY37160A UY0001037160A UY37160A UY37160A UY 37160 A UY37160 A UY 37160A UY 0001037160 A UY0001037160 A UY 0001037160A UY 37160 A UY37160 A UY 37160A UY 37160 A UY37160 A UY 37160A
Authority
UY
Uruguay
Prior art keywords
avß6
integrine
pirrolidine
antagonist activity
compounds derived
Prior art date
Application number
UY0001037160A
Other languages
English (en)
Inventor
Mary Redmond Joanna
Howard James Campbellcrawford Matthew
Andrew Anderson Niall
Alexandrou Procopiou Panayiotis
Seble Lemma
Martin Pritchard John
Paul Hancock Ashley
Leslie Sollis Steven
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37160A publication Critical patent/UY37160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I): en donde R1, R2y R3, son tal como se los define en la descripción y en las reivindicaciones, o sus sales farmacéuticamente aceptables, que tienen una actividad antagonista de la integrina avß6, a composiciones farmacéuticas que incluyen dicho compuesto o una sal del mismo, y al uso de dicho compuesto o una sal del mismo en terapia, incluso en el tratamiento de una enfermedad o afección para la cual está indicado un antagonista de la integrina avß6, y en particular, en el tratamiento de fibrosis pulmonar idiopática.
UY0001037160A 2016-03-21 2017-03-20 COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 UY37160A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1604681.5A GB201604681D0 (en) 2016-03-21 2016-03-21 Chemical Compounds

Publications (1)

Publication Number Publication Date
UY37160A true UY37160A (es) 2017-09-29

Family

ID=55968580

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037160A UY37160A (es) 2016-03-21 2017-03-20 COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6

Country Status (14)

Country Link
US (1) US20210206758A1 (es)
EP (1) EP3433255A1 (es)
JP (1) JP2019509305A (es)
KR (1) KR20180128404A (es)
CN (1) CN108779114A (es)
AR (1) AR107927A1 (es)
AU (1) AU2017237362A1 (es)
BR (1) BR112018069302A2 (es)
CA (1) CA3018014A1 (es)
GB (1) GB201604681D0 (es)
RU (1) RU2018136888A (es)
TW (1) TW201808949A (es)
UY (1) UY37160A (es)
WO (1) WO2017162572A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3589627A4 (en) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
WO2020047207A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020081154A1 (en) 2018-08-29 2020-04-23 Morphic Therapeutic, Inc. INHIBITORS OF ανβ6 INTEGRIN
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
CN113620938A (zh) * 2020-05-07 2021-11-09 北京康派森医药科技有限公司 一种恩格列净异构体杂质的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7743400A (en) * 1999-10-04 2001-05-10 Merck & Co., Inc. Integrin receptor antagonists
EA200200548A1 (ru) * 1999-11-08 2002-10-31 Мерк Энд Ко., Инк. Способ получения антагонистов альфа-v-интегрина на основе имидазолидинона и промежуточные соединения для их получения
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
CN102659946A (zh) 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US9067949B2 (en) 2011-01-19 2015-06-30 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US20150178760A1 (en) 2012-07-24 2015-06-25 Empire Technology Development Llc Methods for valuation of recycling credits
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
RU2018136888A (ru) 2020-04-22
US20210206758A1 (en) 2021-07-08
CA3018014A1 (en) 2017-09-28
GB201604681D0 (en) 2016-05-04
BR112018069302A2 (pt) 2019-01-22
WO2017162572A1 (en) 2017-09-28
AR107927A1 (es) 2018-06-28
EP3433255A1 (en) 2019-01-30
KR20180128404A (ko) 2018-12-03
CN108779114A (zh) 2018-11-09
TW201808949A (zh) 2018-03-16
AU2017237362A1 (en) 2018-08-09
JP2019509305A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
CL2018002803A1 (es) Antagonistas de c5ar solubles
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
DOP2015000216A (es) Inhibidores de bromodominios tetraciclicos
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
UY37205A (es) Inhibidores de bromodominios
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
EA201692003A1 (ru) Макроциклические производные пиримидина
CR20170003A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201692000A1 (ru) Макроциклические производные пиридина
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201692298A1 (ru) Производные карбоксамидов

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204